What is BB Biotech AG Earnings Yield (Joel Greenblatt) %?
BB Biotech AG's Enterprise Value for the quarter that ended in Mar. 2024 was €0.0 Mil.
BB Biotech AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil. BB Biotech AG's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2024 was 0.00%.
The historical rank and industry rank for BB Biotech AG's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of BB Biotech AG was 5.40%. The lowest was 0.00%. And the median was 3.60%.
LSE:0JYO's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -15.45 * Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. BB Biotech AG's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
BB Biotech AG Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for BB Biotech AG's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
BB Biotech AG Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, BB Biotech AG's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's Earnings Yield (Joel Greenblatt) % falls into.
BB Biotech AG Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
BB Biotech AGs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
BB Biotech AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.
BB Biotech AG (LSE:0JYO) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
BB Biotech AG Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of BB Biotech AG's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:0JYO has been successfully added to your 